{
    "clinical_study": {
        "@rank": "87292", 
        "arm_group": [
            {
                "arm_group_label": "Exparel", 
                "arm_group_type": "Experimental", 
                "description": "266 mg Exparel, single-dose injection."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.9% Normal saline, single-dose injection."
            }
        ], 
        "brief_summary": {
            "textblock": "Exparel is a new local analgesic (numbing medication) that is intended to be longer acting\n      than currently available local analgesics. The purpose of this study is to determine whether\n      use of Exparel to numb the nerves along the breastbone after open heart surgery, will\n      decrease pain and pain medication use after surgery."
        }, 
        "brief_title": "Parasternal Nerve Block in Cardiac Patients", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Pain, Postoperative"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Pain, Postoperative"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2, single-institution, randomized, double-blind, parallel-group,\n      placebo-controlled trial of patients undergoing a median sternotomy for primary\n      cardiopulmonary bypass grafting (CABG) surgery.\n\n      78 subjects (39 per treatment arm) will be randomized in a 1:1 ratio to receive a\n      single-dose, parasternal nerve block with either 266 mg Exparel or placebo (0.9% normal\n      saline solution). The nerve blocks will be performed under direct visualization at the end\n      of surgery, just prior to sternal closure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 years old\n\n          -  non-emergent coronary artery bypass grafting surgery (on and off pump)\n\n          -  median sternotomy\n\n        Exclusion Criteria:\n\n          -  Concomitant cardiac procedures (e.g. aortic valve repair/replacement, mitral valve\n             repair/replacement, aortic root replacements).\n\n          -  Redo sternotomy.\n\n          -  < 50 kg (Exparel\u00ae is currently only approved in patients > 50 kg).\n\n          -  Pregnant or nursing\n\n          -  History of alcohol, narcotic or illicit drug abuse\n\n          -  Participation in another study evaluating investigational medications within the past\n             30 days\n\n          -  Taking narcotic analgesics within 3 days pre-operatively or perioperative stress-dose\n             steroids.\n\n          -  Chronic non-cardiac pain (e.g. lower back pain, fibromyalgia) requiring narcotic\n             analgesics.\n\n          -  Pre-operative mild liver insufficiency as defined by liver function tests [(i.e.\n             alanine aminotransferase (ALT), aspartate aminotransferase (AST)] \u2265 1.5 times the\n             upper limit of normal (ULN: ALT: 0-35 U/L, AST: 0-35 U/L, Alk Phos 35-105 U/L, Total\n             bilirubin: 0-1.2 mg/dL)\n\n          -  Pre-operative mild renal insufficiency (Cr \u2265 1.5 mg/dL)\n\n          -  Allergy to amide-type anesthetics\n\n          -  Recurrent ventricular arrhythmias, low cardiac output requiring inotrope and/or\n             intra-aortic balloon pump support, left ventricular ejection fraction < 30% at time\n             of pre-operative screening/evaluation.\n\n          -  Unable to provide informed consent or unable to understand how to use pain rating\n             scales.\n\n          -  Inability to understand or operate the patient-controlled analgesia (PCA) machine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01826851", 
            "org_study_id": "RSRB 00044181"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exparel", 
                "description": "Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.\nPost-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU.", 
                "intervention_name": "Exparel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SKY0402", 
                    "Bupivacaine liposome extended-release injectable suspension"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.\nPost-surgical pain management will be the same as for the Exparel group.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Preservative-free normal saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bupivacaine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pain management", 
            "Anesthetic, local", 
            "Nerve blockade", 
            "Coronary Artery Bypass Surgery", 
            "Analgesics, opioid", 
            "Postoperative complications", 
            "Bupivacaine"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14642"
                }, 
                "name": "University of Rochester Medical Center"
            }, 
            "investigator": {
                "last_name": "Peter A Knight, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Parasternal Intercostal Nerve Block in Post-Cardiac Surgery Patients: A Randomized, Controlled Trial of Extended-release Liposomal Bupivacaine (Exparel) Versus Placebo", 
        "other_outcome": [
            {
                "description": "Change in inspiratory capacity (IC) will be measured in mL with a bedside incentive spirometer. Baseline measurement of IC will be done pre-operatively on day of surgery. Post-operative measurement of IC will be done on post-operative day #1-2.", 
                "measure": "Change in inspiratory capacity (mL)", 
                "safety_issue": "No", 
                "time_frame": "2 days"
            }, 
            {
                "description": "The safety of Exparel will be assessed by the occurrence of all adverse events and serious events up through 30 days.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "overall_contact": {
            "email": "Peter_Knight@urmc.rochester.edu", 
            "last_name": "Peter A Knight, MD", 
            "phone": "(585) 275-6340"
        }, 
        "overall_contact_backup": {
            "email": "Candice_Lee@urmc.rochester.edu", 
            "last_name": "Candice Y Lee, MD", 
            "phone": "(585) 276-3458"
        }, 
        "overall_official": {
            "affiliation": "University of Rochester", 
            "last_name": "Peter A Knight, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The efficacy of Exparel will be assessed by: (1) Pain score assessment (Nonverbal Pain Score and Numerical Rating Scale) up through 72 hours, and (2) Cumulative opioid requirements up through 72 hours.", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01826851"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Rochester", 
            "investigator_full_name": "Peter A Knight", 
            "investigator_title": "Professor, Cardiac Surgery", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to extubation (hours)", 
                "safety_issue": "No", 
                "time_frame": "16 hours"
            }, 
            {
                "measure": "ICU Length of stay (hours)", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Time to return of bowel function (days)", 
                "safety_issue": "No", 
                "time_frame": "10 days"
            }, 
            {
                "measure": "Hospital length of stay (days)", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "University of Rochester", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peter A Knight", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}